Company intelligence / Profile preview

ImmunityBio, Inc.

San Diego, California, United States of Americalinkedin.com ↗

Ownership: Public · IBRX
Employees: ~680
Development stage: Phase 3

Overview

ImmunityBio has received FDA approval for ANKTIVA, the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS. The company has 27 clinical trials, with 18 in Phase 2 or 3 development across 13 indications in liquid and solid tumors.

Therapeutic areas: OncologyInfectious Diseases
Modalities: ImmunotherapiesCell therapiesAntibody cytokine fusion proteinsVaccinesNatural killer cell platform
Industry: Biotech

Drug pipeline

61 assets

nogapendekin alfa

Approved

60 more assets in the full pipeline.

Request access →

Partnerships

BeiGene, Ltd.National Cancer Institute (NCI)nCartes, Inc.

Financials

Market cap: $8.1B
Total revenue: $51.2M
Enterprise value: $8.5B

Beyond the preview

Go deeper on ImmunityBio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunityBio, Inc..

Explore the full profile